Ginkgo Bioworks Surges on Eli Lilly AI Drug Discovery Partnership

What happened

Ginkgo Bioworks announced a partnership with Eli Lilly focused on AI-driven drug discovery, sending its shares up sharply and more than doubling from prior levels. The agreement marks a significant validation of Ginkgo's cell engineering and AI platform by a major pharmaceutical company, especially amid the company's ongoing restructuring and pivot toward fee-for-service models. However, the company's financial position remains precarious, with cash and restricted cash down to $251 million as of mid-2025 and quarterly negative free cash flow of $40-44 million. While the partnership has generated enthusiasm, details regarding economics, milestone payments, and revenue contribution have not been disclosed, making the stock's reaction potentially premature. For investors, the deal is a positive signal of platform credibility, but it does not resolve near-term liquidity and profitability challenges.

Implication

The Eli Lilly collaboration is a meaningful endorsement that could open doors to additional pharmaceutical partnerships, but its financial impact is uncertain pending contract terms. Ginkgo's cash runway remains limited, and without a rapid improvement in free cash flow, the company may need to raise capital, diluting existing shareholders. The stock's doubling appears driven by sentiment rather than fundamental earnings, and such moves can be vulnerable to reversal if milestones disappoint. Long-term investors should monitor whether Ginkgo can convert this high-profile deal into recurring revenue and whether it accelerates the path to adjusted EBITDA breakeven targeted for end-2026. On balance, while the partnership improves the company's strategic positioning, we maintain a cautious stance until evidence of financial stabilization emerges.

Thesis delta

Previously, the thesis centered on whether Ginkgo could execute its restructuring and convert optionality from partnerships like Merck and Boehringer. The Lilly deal introduces a new, high-visibility validation that strengthens platform credibility but does not yet alter the core financial challenges of cash burn and revenue scale. As a result, the thesis shifts from a broad 'show me' story to a focused question of whether Lilly milestones can be realized and monetized quickly enough to address liquidity.